secwatch.observer — SEC 8-K summary
======================================

Issuer:     SIGA TECHNOLOGIES INC (SIGA)
CIK:        0001010086
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001140361-24-024697
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend
-----------------------------------------------------------------------------

- Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.
- Operating income $11.3M vs loss $2.1M YoY; net income $10.3M vs loss $0.9M; diluted EPS $0.14 vs ($0.01).
- Partner Japan Biotechno Pharma filed NDA for tecovirimat in Japan for smallpox, mpox, etc. on April 11, 2024.
- Amendment to Meridian agreement: SIGA takes over international promotion of oral TPOXX effective June 1, 2024.
- Special cash dividend of $0.60 per share declared March 12, paid April 11, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/0001140361-24-024697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/ef20028413_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-024697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer